Expediency of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with ovarian cancer. Discussion aspects | Український Медичний Часопис

Manzhura O.P.,Osynsky D.S.,Kuhar I.V.,Maistrenko Ye.V.,Merentsev S.P.,Mickiewicz V.Ye.,Garasymchuk L.V.,Chaika Yu.A.,Kondratenko A.V.

Головна
Публікації
Expediency of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with ovarian cancer. Discussion aspects

Expediency of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with ovarian cancer. Discussion aspects

26 серпня 2021

824

Obstetrics and Gynecology

Ключові слова :

cytoreductive surgery,

hyperthermic intra-abdominal chemotherapy,

ovarian cancer,

relapse-free and overall survival

Спеціальності :

Obstetrics and Gynecology

Oncology, Hematology

Surgery

Резюме

Treatment for advanced ovarian cancer usually involves cytoreductive surgery and systemic chemotherapy in combination with targeted. The results of treatment are still disappointing and rate of mortality 9.0 per 100,000 female population, regardless of age. This led to the study of new treatments, namely, hyperthermic intra-abdominal chemotherapy in combination with cytoreductive. We have analyzed various studies and studies based on which the use of HIPEC combination with cytoreduction recurrence-free survival for patients with advanced ovarian cancer by 3.5 months and the overall survival rate by 11.8 months.

References:

1. ecis.jrc.ec.europa.eu/.
2. http://www.ncru.inf.ua/publications/index.htm.
3. World Health Organization (2020) Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2019 (who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death).
4. Committeeon Gynecologic Practice, Society of Gynecologic Oncology (2017) Committee Opinion No. 716: Ther ole of the obstetrician-gynecologist in thee arlyde tection of epithelial ovarian cancer in women ataverage risk. American College of Obstetricians and Gynecologists. Obstet. Gynecol., 130(3): 146–149.
5. Ferlay J., Colombet M., Soerjomataram I. et al. (2018) Global and Regional Estimates of the Incidence and Mortality for 38 Cancers: GLOBOCAN 2018. International Agency for Research on Cancer/World Health Organization.
6. Ferlay J., Colombet M., Soerjomataram I. et al. (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods Int. J. Cancer, 144: 1941–1953.
7. Xie F., Van Bocxlaer J., Colin P. et al. (2020) PKPD Modeling and Dosing Considerations in Advanced Ovarian Cancer Patients Treated with Cisplatin-Based Intraoperative Intraperitoneal Chemotherapy. The AAPS J., 22(5): 1–12.
8. Chambers L.M., Costales A.B., Crean-Tate K. et al. (2020) A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology. Gynecol. Oncol., 158(3): 794–802. doi: 10.1016/j.ygyno.2020.06.487.
9. Cianci S., Riemma G., Ronsini C. et al. (2020) Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer recurrence: systematic review and meta-analysis. gs.amegroups.com/article/view/44562/html.
10. Spiliotis J., Iavazzo Ch., Fotiou A. et al. (2021) Upfront or intermediate treatment of advanced ovarian cancer patients with cytoreduction plus HIPEC: Results of a retrospective study. J. Surg. Oncol., 123(2): 630–637. doi: 10.1002/jso.26280.
11. Mishra M., Singh N., Ghatage P. (2021) Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer. Cureus, 13(6): e15563. doi:10.7759/cureus.15563
12. Friedrich M., Zinn W., Kolnsberg L. et al. (2020) Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer: Evaluation of Side Effects in a Single Institution Cohort. Anticancer Res., 40(3): 1481–1486. doi: 10.21873/anticanres.14092.
13. Koole S.N., Kieffer J.M., Sikorska K. et al. (2021) Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer. Eur. J. Surg. Oncol., 47(1): 101–107.
14. van Driel W.J., Koole S.N., Sikorska K. et al. (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. New Engl. J. Med., 378(3): 230–240.
15. Lustosa R.J.C., Batista Th.P., Carneiro V.C.G. et al. (2020) Quality of life in a phase 2 trial of short-course hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking surgery for high tumor burden ovarian cancer. Rev. Col. Bras. Cir., 47: e20202534. doi: 10.1590/0100-6991e-20202534.
16. Lei Z., Wang Y., Wang J. et al. (2020) Evaluation of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer. JAMA Netw Open, 3(8): e2013940.
17. Helm C.W., Richard S.D., Pan J. et al. (2010) Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int. J. Gynecol. Cancer, 20(1): 61–69. doi: 10.1111/IGC.0b013e3181c50cde.
18. clinicaltrials.gov/ct2/show/NCT03772028.